Nanoformulation of the superoxide dismutase mimic, MnTnBuOE-2-PyP5+, prevents its acute hypotensive response

Schlichte, Sarah L.; Romanova, Svetlana; Katsurada, Kenichi; Kosmacek, Elizabeth A.; Bronich, Tatiana K.; Patel, Kaushik P.; Oberley‐Deegan, Rebecca E.; Zimmerman, Matthew C.

doi:10.1016/j.redox.2020.101610

Cited by 5 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Schlichte (2020) developed a mesoporous silica nanoparticle and lipid bilayer nanoformulation of MnTnBuOE-2-PyP 5+ . The nanoformulation allows a slow and sustained release of the drug, thus reducing the acute reduction in renal sympathetic nerve activity induced by the injection of the free drug [ 316 ].…”

Section: Sod Sourcesmentioning

confidence: 99%

Superoxide Dismutase Administration: A Review of Proposed Human Uses

et al. 2021

View full text Add to dashboard Cite

Superoxide dismutases (SODs) are metalloenzymes that play a major role in antioxidant defense against oxidative stress in the body. SOD supplementation may therefore trigger the endogenous antioxidant machinery for the neutralization of free-radical excess and be used in a variety of pathological settings. This paper aimed to provide an extensive review of the possible uses of SODs in a range of pathological settings, as well as describe the current pitfalls and the delivery strategies that are in development to solve bioavailability issues. We carried out a PubMed query, using the keywords “SOD”, “SOD mimetics”, “SOD supplementation”, which included papers published in the English language, between 2012 and 2020, on the potential therapeutic applications of SODs, including detoxification strategies. As highlighted in this paper, it can be argued that the generic antioxidant effects of SODs are beneficial under all tested conditions, from ocular and cardiovascular diseases to neurodegenerative disorders and metabolic diseases, including diabetes and its complications and obesity. However, it must be underlined that clinical evidence for its efficacy is limited and consequently, this efficacy is currently far from being demonstrated.

show abstract

Section: Sod Sourcesmentioning

confidence: 99%

Superoxide Dismutase Administration: A Review of Proposed Human Uses

et al. 2021

View full text Add to dashboard Cite

show abstract

“…So far, numerous small molecular radioprotectors of both natural and synthetic origin have been developed to protect normal tissues from radiation, such as amifostine, curcumin, glycyrrhizic acid, melanin, caffeic acid, baicalein, dihydropyridines, MnTnBuOE-2-PyP 5+ , etc. [689][690][691][692][693][694][695] However, these small molecular radioprotectors exhibit poor bioavailability and short blood circulation half-life, resulting in limited protective efficacy. 696 Advanced nanotechnology promises to overcome these challenges.…”

Section: Nanocarriers To Deliver Small Molecular Radioprotectorsmentioning

confidence: 99%